Phase I Clinical Study on the Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) Injection in Patients With Acute Ischemic Stroke
Latest Information Update: 26 Feb 2025
At a glance
- Drugs Endothelial-progenitor-cell-therapy-Allife-Medical-Science-and-Technology (Primary)
- Indications Ischaemic stroke
- Focus Adverse reactions
- Sponsors Allife Medical Science and Technology
Most Recent Events
- 20 Sep 2024 Status changed from not yet recruiting to active, no longer recruiting.
- 20 Sep 2024 Planned End Date changed from 15 Aug 2025 to 15 Apr 2025.
- 20 Sep 2024 Planned primary completion date changed from 15 Aug 2024 to 15 Apr 2025.